Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Teva’s Orphan Leukemia Drug Lands Accelerated Approval

Drug Industry Daily

Oct. 29, 2012 | Vol. 11 No. 212

Teva’s Orphan Leukemia Drug Lands Accelerated Approval

Teva plans to launch its orphan chronic myeloid leukemia (CML) drug Synribo by mid-November after getting accelerated approval Friday.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

The Buzz Lilly Phase III Non-Hodgkin’s Lymphoma Drug Trial Halted Lilly’s Ramucirumab Disappoints With Small Overall Survival Advantage: Analysts Astellas Submits sNDA for Tarceva as First-Line Lung Cancer Treatment

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.